LYNPARZA^® (olaparib)Plus Abiraterone and Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck announced that LYNPARZA in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated mCRPC.